| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/CHMP/48737/2012 (20.1.12) |
| Publication Date | 20/01/2011 |
| Content Type | News |
|
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), in January 2012, recommended approval of a new medicine intended for the treatment of Cushing’s disease in patients who cannot have surgery or for whom surgery has not been successful. Cushing’s disease is a very rare, debilitating and life-threatening disease, where a small tumour of the pituitary (an endocrine gland) makes too much of the hormone adrenocorticotrophin (ACTH), which in turn stimulates the adrenal glands to both grow and release excessive amounts of cortisol in the blood. |
|
| Source Link | http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/01/news_detail_001426.jsp&mid=WC0b01ac058004d5c1 |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe |
